Sarepta Therapeutics

Sarepta, AcelRx Look to Infuse Some Cash into Their Pipelines
Sarepta, AcelRx Look to Infuse Some Cash into Their Pipelines
BioSpace
Sarepta Therapeutics
AcelRx
stock offering
Flag link:
Myonexus Therapeutics Starts Trial of First-Ever Gene Therapy for Rare Type of Muscular Dystrophy
Myonexus Therapeutics Starts Trial of First-Ever Gene Therapy for Rare Type of Muscular Dystrophy
CP Wire
Myonexus
Sarepta Therapeutics
muscular dystrophy
gene therapy
Flag link:
Myonexus Therapeutics Starts Trial of First-Ever Gene Therapy for Rare Type of Muscular Dystrophy
Myonexus
Sarepta Therapeutics
muscular dystrophy
Flag link:
Antisense startup Stoke Therapeutics secures another $90M in series B funding
Antisense startup Stoke Therapeutics secures another $90M in series B funding
Endpoints
Stoke Therapeutics
Sarepta Therapeutics
Flag link:
Sarepta Gene Therapy Appears To Help Fourth Boy With Duchenne Muscular Dystrophy
Sarepta Gene Therapy Appears To Help Fourth Boy With Duchenne Muscular Dystrophy
Forbes
Sarepta Therapeutics
Duchenne Muscular Dystrophy
gene therapy
Flag link:
FDA lifts clinical hold on Sarepta's Duchenne MD gene therapy, clearing the way to a quick launch of a pivotal trial
FDA lifts clinical hold on Sarepta's Duchenne MD gene therapy, clearing the way to a quick launch of a pivotal trial
Endpoints
Sarepta Therapeutics
FDA
gene therapy
Duchenne Muscular Dystrophy
clinical trials
Flag link:
Europe Advisory Panel Rejects Sarepta’s Duchenne Drug Once Again
Europe Advisory Panel Rejects Sarepta’s Duchenne Drug Once Again
Xconomy
Europe
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
eteplirsen
Flag link:
Sarepta Invests $30 Million in Gene Therapy Company
Sarepta Invests $30 Million in Gene Therapy Company
CP Wire
Lacerta Therapeutics
Sarepta Therapeutics
gene therapy
Flag link:
Sarepta Invests $30 Million in Gene Therapy Company
Lacerta Therapeutics
Sarepta Therapeutics
Flag link:
Sarepta all-in on gene therapy pipeline, adding 3 CNS treatments in $30M Lacerta deal
Sarepta all-in on gene therapy pipeline, adding 3 CNS treatments in $30M Lacerta deal
Endpoints
Sarepta Therapeutics
CNS
Pompe disease
Lacerta
Flag link:
FDA slaps a hold on Sarepta’s Duchenne MD study in the wake of stellar early results
FDA slaps a hold on Sarepta’s Duchenne MD study in the wake of stellar early results
Endpoints
Sarepta Therapeutics
Duchenne Muscular Dystrophy
FDA
clinical hold
gene therapy
Flag link:
3 Best Gene Therapy Stocks of 2018 (So Far)
3 Best Gene Therapy Stocks of 2018 (So Far)
Motley Fool
gene therapy
FDA
Sarepta Therapeutics
Solid Biosciences
Regnxbio
Flag link:
[video/transcript]Sarepta Therapeutics Could Be Onto Something Big
[video/transcript]Sarepta Therapeutics Could Be Onto Something Big
Motley Fool
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Flag link:
Why PTC Therapeutics Dropped 30.6% Today After Jumping 27.5% Yesterday
Why PTC Therapeutics Dropped 30.6% Today After Jumping 27.5% Yesterday
Motley Fool
PTC Therapeutics
risdiplam
Biogen
Ionis Pharmaceuticals
spinal muscular atrophy
Sarepta Therapeutics
Translarna
Emflaza
Flag link:
3 patients add $2.5B to Sarepta's value
3 patients add $2.5B to Sarepta's value
Biopharma Dive
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Flag link:
With tantalizing early results, Sarepta’s gene therapy for Duchenne raises hopes for ‘real change’
With tantalizing early results, Sarepta’s gene therapy for Duchenne raises hopes for ‘real change’
Stat
Sarepta Therapeutics
Duchenne Muscular Dystrophy
clinical trials
Flag link:
As Sarepta Preps Data, FDA Lifts Hold on Solid’s Duchenne Gene Therapy
As Sarepta Preps Data, FDA Lifts Hold on Solid’s Duchenne Gene Therapy
Xconomy
Duchenne Muscular Dystrophy
Solid Biosciences
Sarepta Therapeutics
SGT-001
Flag link:
Sarepta CEO Doug Ingram scored a chart-topping $57M compensation deal in 2017. Earning it won’t be easy
Sarepta CEO Doug Ingram scored a chart-topping $57M compensation deal in 2017. Earning it won’t be easy
Endpoints
Sarepta Therapeutics
Doug Ingram
executive pay
Flag link:
Sarepta’s eteplirsen spurned as European regulators turn thumbs down on controversial Duchenne MD drug
Sarepta’s eteplirsen spurned as European regulators turn thumbs down on controversial Duchenne MD drug
Endpoints
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
Exondys 51
CHMP
Europe
Flag link:
Should Sarepta’s patents be seized by the government? Patient advocates pitch controversial drug pricing proposal
Should Sarepta’s patents be seized by the government? Patient advocates pitch controversial drug pricing proposal
Endpoints
Sarepta Therapeutics
patients
patents
Exondys 51
Duchenne Muscular Dystrophy
Flag link:

Pages